Release details

2018-03-08 14:38 CET
  • Print
  • Share Share
en

Verona Pharma plc : 1st Quarter Results

LONDON, March 08, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that, on March 7, 2018, Dr. Jan-Anders Karlsson, Chief Executive Officer of the Company, purchased 3,250 ordinary shares of 5 pence each in the Company (the "Ordinary Shares") at a price of 148.64 pence per Ordinary Share.  Following the acquisition, Dr. Karlsson will have an interest in the Company of 92,400 Ordinary Shares, representing 0.09% of the Company's issued share capital.

The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.

1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Jan-Anders Karlsson

 
2 Reason for the notification
 

a)

 
 

Position/status

 
Chief Executive Officer
b)

 
Initial notification/Amendment

 
Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name Verona Pharma plc
b) LEI

 
213800EVI6O6J3TIAL06

 
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument

Identification code
Ordinary Shares of 5 pence each

GB00BYW2KH80
b) Nature of the transaction

 
Jan-Anders Karlsson purchased 3,250 Ordinary Shares
c) Price(s) and volume(s) Price(s) Volume(s)
    148.64 pence per 
Ordinary Share
3,250 Ordinary 
Shares
d) Aggregated information

-  Aggregated volume
-  Price
N/A

 
e) Date of the transaction

 
7 March 2018
f) Place of the transaction

 
London Stock Exchange, AIM
     

For further information, please contact:

Verona Pharma plc Tel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officer info@veronapharma.com
   
Stifel Nicolaus Europe Limited (Nominated Adviser
and UK Broker)
Tel: +44 (0) 20 7710 7600
SNELVeronaPharma@stifel.com
Stewart Wallace / Jonathan Senior / Ben Maddison  
HUG#2174735